Navigation Links
Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users
Date:10/26/2009

SAN DIEGO, Oct. 26 /PRNewswire/ -- Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today presented an analysis from two pivotal Phase 3 trials (REDUCE-1 and REDUCE-2) evaluating its lead investigational compound HZT-501, a combination of ibuprofen with high-dose famotidine. The analysis, which was designed to identify risk factors for the development of non-steroidal anti-inflammatory drug (NSAID)-associated ulcers, was presented at the 74th American College of Gastroenterology (ACG) Annual Scientific Meeting.

"Upper gastrointestinal tract ulcers develop commonly in people taking NSAIDs and can occur without warning symptoms. Historically there have been limited data identifying the factors that predict an increased risk of finding ulcers in NSAID users," said Loren Laine, MD, University of Southern California Keck School of Medicine and lead investigator. "Data collected from the REDUCE-1 and REDUCE-2 trials provide insight into these risk factors. The statistically significant independent risk factors included the use of the NSAID ibuprofen without the histamine-2 receptor antagonist famotidine, previous ulcer disease and older age."

The two pivotal Phase 3 clinical trials, REDUCE-1 and REDUCE-2 (Registration Endoscopic Studies to Determine Ulcer Formation of HZT-501 Compared to Ibuprofen: Efficacy and Safety Studies), conducted via a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA), were randomized, double-blind, controlled trials that enrolled more than 1500 patients with mild-to-moderate pain. Patients were randomly assigned, in approximately a 2:1 ratio, to receive either HZT-501 (800 mg ibuprofen and 26.6 mg famotidine) or the NSAID ibuprofen (800 mg) alone orally three times daily for a 24-week treatment period or until patients developed either an endoscopically diagnosed upper gastrointestinal (GI) ulcer and/or prohibitive toxicity. Results showed that patients with mild-to-moderate pain treated with HZT-501 developed approximately 50 percent fewer NSAID-associated upper GI ulcers compared to patients treated with ibuprofen alone.

The statistical analysis looked at the combined 1,382 patients studied in the REDUCE-1 and REDUCE-2 primary study populations (HZT-501, N=930; ibuprofen, N=452). The predefined population for primary analyses of upper GI ulcers was all patients with at least one on-study endoscopy (EGD). The life table analysis estimate showed that fewer patients taking HZT-501 developed upper GI ulcers than those taking ibuprofen alone after 24 weeks (14.1% vs. 26.5%, p<0.0001). A multivariable proportional hazard regression analysis was done to assess potential risk factors for upper GI ulcer development in the combined studies. The following chart highlights the most prevalent risk factors derived from the analysis:



                   Analysis Factor                Relative Risk (95% CI)
                   ---------------                ---------------------
           Ibuprofen (without famotidine)           2.18 (1.64, 2.90)

                     Prior ulcer                    1.65 (1.01, 2.69)

                      Age >=65                      1.54 (1.10, 2.17)

                  Low-dose aspirin                  1.46 (1.00, 2.11)

                       Female                       1.15 (0.84, 1.57)

       Baseline erosions (GI erosions noted on
        baseline endoscopy at the start of the
        study)                                      1.15 (0.82, 1.62)


"By identifying these independent risk factors, physicians may be able to better assess a patient's risk for NSAID-associated GI toxicity," said Timothy P. Walbert, president and chief executive officer of Horizon Therapeutics. "For patients with chronic pain who are at increased GI risk, HZT-501 may be an important treatment option."

About HZT-501

HZT-501 is a novel, proprietary fixed-dose tablet combining the most prescribed NSAID in the U.S., ibuprofen, with a high dose of the most potent H2 antagonist, famotidine, in a single pill. It is anticipated that HZT-501 will provide effective pain relief and reduce stomach acidity during the peak time of ulceration risk, thus reducing the risk of NSAID-associated upper GI ulcers.

About the Arthritis and Pain Market

According to the Arthritis Foundation, arthritis affects 46 million people in the U.S. and costs the U.S. economy $128 billion annually. According to a study by the Centers for Disease Control and Prevention (CDC) for the National Arthritis Data Workgroup, due to the increasing aging population, arthritis is projected to increase by 40 percent in the next two decades. The CDC estimates that 67 million people will be affected by arthritis by 2030. Additionally, chronic pain affects an estimated 86 million American adults. NSAIDs are among the most widely used drugs in the world for the treatment of arthritis and pain and are a major cause of GI complications, including ulcers. NSAIDs block enzymes and reduce prostaglandins throughout the body and as a consequence, ongoing inflammation, pain, and fever are reduced. Because the prostaglandins that protect the stomach are reduced, NSAIDs often cause ulcers in the stomach. NSAID-induced GI toxicity causes an estimated 16,500 deaths and more than 107,000 hospitalizations annually in the U.S. alone.

If deaths from the gastrointestinal effects of NSAIDs were tabulated separately in the National Vital Statistics reports, these effects would equate to the 15th most common cause of death in the U.S. Studies have shown that less than 30 percent of high-risk NSAID patients are co-prescribed a gastro-protective agent in combination with their NSAID. In addition, patient adherence to a regimen of separate pain and GI protective medications has been shown to be poor.

About Horizon Therapeutics

Horizon Therapeutics, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of mild-to-moderate pain and arthritis. Horizon's clinical portfolio includes innovative combination therapies in early- and late-stage development that are designed to improve safety, efficacy and patient compliance. For more information about the company and its products, please visit www.horizontherapeutics.com.

SOURCE Horizon Therapeutics, Inc.


'/>"/>
SOURCE Horizon Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Horizon Therapeutics HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients With Mild-to-Moderate Pain
2. Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
3. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
4. HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS(R) Drug-Eluting Stents in Heart Attack Patients
5. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
6. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
7. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
8. Inhibikase Therapeutics Discusses New Platform for Infectious Disease Pharmaceuticals at BIOCOM 2009
9. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual BIO Investor Forum
10. Cell Therapeutics, Inc. Reports Outcome of Annual Meeting of Shareholders
11. Logical Therapeutics to Present Data on LT-NS001 at American College of Gastroenterology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... January 23, 2017 Ahead of today,s trading ... how they have fared at the close: Kite Pharma Inc. (NASDAQ: ... OVAS ), and Regeneron Pharmaceuticals Inc. (NASDAQ: ... were relative laggards on Friday, January 20 th , 2017, down ... research reports on these stocks now at: ...
(Date:1/23/2017)... , January 23, 2017 A new ... Testing Market was valued at US$0.53 bn in 2013 and ... a strong 17.50% CAGR between 2014 and 2022. The title of ... Analysis, Size, Volume, Share, Growth, Trends and Forecast 2014 - 2022." ... Non-invasive prenatal testing ...
(Date:1/23/2017)... The global  anxiety disorders and depression treatment market  is expected to reach ... worldwide is anticipated to drive the market growth in the coming years. Increasing ... in the recent years. Continue Reading ... ... ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... January 23, 2017 , ... ... Living (IHCA/INCAL), will serve as a healthcare industry expert at the 2017 Sector ... discussion, moderated by Inside Indiana Business host Gerry Dick, will feature an employer ...
(Date:1/23/2017)... Greifensee, Switzerland (PRWEB) , ... January 23, 2017 ... ... many lab and production applications. However, choosing the right method is paramount to ... may occur more often in situations where multiple persons use the same equipment. ...
(Date:1/23/2017)... ... 23, 2017 , ... "ProRandom is a set of camera tools that allow video editors to ... Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , With ... with video footage. ProRandom works by using a virtual camera to create the illusion ...
(Date:1/23/2017)... (PRWEB) , ... January 23, ... ... Education Foundation (OREF), in partnership with the American Society of Anesthesiologists® (ASA®), ... Foundation (APSF), the American Academy of Orthopaedic Surgeons (AAOS) and the Cigna ...
(Date:1/23/2017)... , ... January 23, 2017 , ... “The Inn at the Mill”: a story ... fears in her quest to become happy and content. , “The Inn at the ... has also lived in Germany and Vermont and is now living in Berks County on ...
Breaking Medicine News(10 mins):